Abstract Objective This study sought to evaluate the efficacy of Mindfulness-based Stress Reduction (MBSR) on symptoms of posttraumatic stress, depression, anxiety, and perceived stress and quality of life in unstably-housed women undergoing substance use disorder (SUD) treatment. Despite the potential for MBSR to be a helpful adjunct to ongoing care, prior research on the benefit of MBSR in...
CureusOctober 1, 2025Xinmin Jiang, Minghui Zhang, Jiaqi Wang et al.
This meta-analysis was conducted to investigate the effect of mindfulness-based stress reduction (MBSR) on the treatment and improvement of traumatic stress disorder (PTSD). Up until February 6, 2025, PubMed, Web of Science, and Embase databases were searched for randomized controlled trials of MBSR-based treatment for PTSD patients. RevMan 5.4 software (The Cochrane Collaboration, London, UK)...
Obsessive-Compulsive Symptoms (OCS) arise from maladaptive appraisal of intrusive thoughts, for which Adverse Childhood Experiences (ACE) can be a major risk factor, due to distorted senses of responsibility and control. Emerging research suggests Mindfulness-Based Interventions (MBIs) can be beneficial for reducing OCS, but existing mechanistic understandings are still based on exposure...
Major depressive disorder (MDD) has become the second largest risk factor affecting human health, with a progress in its treatment especially non-pharmacological therapies. The loving-kindness meditation (LKM) has been introduced to depression but is not popular due to requirement on awareness and concentration, and its utilization in clinical MDD is absent as well as exploration on neural...
Treatment-resistant depression (TRD) represents a major clinical challenge. Affecting about 30 % of major depressive disorder (MDD) patients, effective treatments for TRD are urgently needed. While depression research and antidepressant (AD) development have long centred on monoaminergic targets, research over the past 35 years has increasingly explored glutamatergic mechanisms. Here we present...
Major depressive disorder (MDD) frequently co-occurs with substance use disorders (SUDs), leading to poorer outcomes and limited options. Esketamine is approved for treatment-resistant depression (TRD); its effects on craving and abstinence in SUD are less explored. A 41-year-old man with recurrent MDD (suicidal ideation) and polysubstance use (daily morphine/prescription opioids; intermittent...
Background: Ketamine, an N-methyl-D-aspartate antagonist, has been used for decades as an anesthetic agent, but more recently it has been studied in psychiatric illness. Though ketamine has been investigated for use in the general population, fewer studies have investigated the efficacy and tolerability of this treatment for older (age >60) adults. Objectives: This review sought to compile the...
After years of restrictions due to concerns about their potentially harmful effects, research on psychedelics has entered a new era. Increasing attention has been directed toward their immense therapeutic potential, particularly for psychiatric disorders. Pre-clinical and clinical studies have consistently demonstrated that psychedelic treatments produce therapeutic effects within hours of...
Suicide is the leading cause of death among adolescents worldwide and has serious implications for socio-economic development. Some studies have found that suicide attempts and suicidal thoughts are more likely to occur in adolescents with depression. In depressed adolescents, cognitive function is often significantly impaired. The cognitive function of depressed adolescents is mainly...
Major depressive disorder, particularly its treatment-resistant form (TRD), poses significant treatment challenges. Ketamine, an N-methyl-d-aspartate receptor antagonist, has shown promise in rapidly alleviating depressive symptoms by influencing neuroplasticity and glutamatergic modulation, which are thought to influence brain activity complexity. In this placebo-controlled study, we examined...
Despite its global recognition, Mindfulness Based Cognitive Therapy (MBCT) remains under-explored in terms of cultural adaptation and effectiveness among older adults in non-Western contexts such as Indonesia, where depression is both prevalent and shaped by cultural perceptions. This study presents a culturally adapted MBCT approach for older Indonesians with depression to enhance its...
Major depressive disorder is a public health issue that negatively impacts quality of life and leads to cognitive impairments, causing significant disruptions in work, education, and social life. Treatment-resistant depression is defined as the failure to achieve improvement in depressive symptoms despite the use of at least two different antidepressant medications at adequate doses and...
Treatment-resistant depression (TRD) remains a major therapeutic challenge in psychiatry, affecting a substantial proportion of individuals diagnosed with major depressive disorder and contributing significantly to the overall burden of mental illness. Despite decades of research and the availability of numerous antidepressant agents, many patients fail to achieve full remission, which...
Treatment-resistant depression (TRD) affected nearly 20–30% of individuals diagnosed with major depressive disorder and remained a significant therapeutic challenge. The lack of response to traditional antidepressant therapies placed a substantial emotional, functional, and economic burden on patients and healthcare systems. In recent years, ketamine and electroconvulsive therapy (ECT) emerged...
Research SquareSeptember 26, 2025Soria López, Cinto Segalàs, Eva Real et al.
preprint
Abstract Background: Intranasal esketamine has gained attention as a rapidly acting intervention for treatment-resistant depression, and there is growing interest in its potential anti-obsessional effects. To our knowledge, no published case series has focused on intranasal esketamine in patients with both treatment-resistant obsessive–compulsive disorder (TR‑OCD) and comorbid major depression...
Ketamine has anti depressive characters and approved by (FDA) for the induction and maintenance of anesthesia, Ketamine has been incorporated into the management of psychiatric disorders, such as Major Depressive Disorder (MDD) especially with suicidal ideation or attempting, and of label in management of Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Obsessive-Compulsive Disorder...
This case report describes the management of a 38-year-old female with recurrent depressive disorder, who presented with severe depressive symptoms and active suicidal ideations. She reported persistent low mood, loss of interest in pleasurable activities, fatigue, and disturbed sleep for nearly three weeks, with recurrent thoughts of ending her life in the preceding week. Despite being on...
Abstract Introduction Treatment-resistant depression (TRD) affects up to one-third of patients with major depressive disorder, leading to poor outcomes and increased suicide risk. Esketamine nasal spray, a novel glutamatergic modulator, has emerged as an adjunctive option with rapid onset of action. However, the efficacy and safety of esketamine across randomized controlled trials (RCTs) remain...
Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression as demonstrated by reductions in Montgomery-Åsberg Depression Rating Scale and Patient-Health Questionnaire-9 total scores and equivocal changes in every item on both rating scales. The magnitude of change in individual items was similar to that of...
Introduction: Treatment-Resistant Depression (TRD) affects approximately 30–50% of patients with Major Depressive Disorder (MDD) who fail to respond to at least two adequate antidepressant trials. This condition presents substantial clinical and functional challenges, and no universally accepted treatment algorithm currently exists. Emerging therapeutic strategies, particularly glutamatergic...